Piper Sandler Lowers Price Target for Amphastar Pharmaceuticals to $21 Amid Pipeline Uncertainty
Piper Sandler reduced its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) from $25 to $21 while maintaining a Neutral rating, citing uncertainty around the timing of pipeline catalysts. The firm highlighted limited clarity regarding when AMPH's complex generic and branded products will generate meaningful results.
